LISA-TRACKER anti-Infliximab
Product Description
LISA-TRACKER anti-Infliximab is an enzyme linked immunoassay (ELISA) for the quantitative determination of human anti-Infliximab antibodies in human serum samples.
- Comprehensive menu in inflammatory diseases and oncology
- Validated on principle drug and biosimilars
- Ready to use reagents
- Standardised protocols from sample collection to result interpretation
- Automation ready – protocols available on several open platform ELISA systems
-
- Afif W et al. Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease. Am J Gastroenterol 2010; 105:1133–1139.
- Baert F et al. Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn’s Disease. N Engl J Med 2003;348:601-8.
- Candon S et al. Clinical and biological consequences of immunization to infliximab in pediatric Crohn’s disease. Clin Immunol. 2006 Jan;118(1):11-9.
- Marotte et al. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther. 2005;7(1):R149-55.
- Radstake TRDJ et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739–1745.
- Seow CH et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010 Jan;59(1):49-54.
- Steenholdt C et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn’s disease. Scandinavian Journal of Gastroenterology, March 2011, Vol. 46, N°3, Pages 310-318.
- Ternant D et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of Infliximab. Ther Drug Monit., 2006 April ; 28(2):169-174.
- Van den Bemt BJF et al. Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study. BMC Musculoskeletal Disorders 2011.
- Metcalfe C et al. World Health Organization, WHO Expert Committee on Biological Standardization. (2017). Report on a collaborative study for proposed 1st international standard for Infliximab. WHO/BS/2017.2323.
- Product Code: LTI-003-48
- Number of Tests: 48
- Sample Type: Serum or plasma
- Sample Volume: 100 μL (following predilution)
- Assay Range: 10 – 200 ng/mL
- Add to Enquiry Basket
Interested? Enquire now.
Add to Enquiry Basket
Related Products
| Assays | Certification | Platform | Clinical Area | Portfolio | RUO/IVD |
|---|---|---|---|---|---|
| LISA-TRACKER Infliximab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Infliximab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Adalimumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Certolizumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Etanercept | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Golimumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Rituximab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Secukinumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Tocilizumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Ustekinumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Vedolizumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD |